ArticleOncotarget2016
New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
- Potential of Fibulin2 as a therapeutic target against cancer and as a diagnostic marker (Review).International journal of oncology · 2025Review
- Molecular roles of microRNA-21 and exosomal miR-21 in gastrointestinal cancers: diagnostic, therapeutic, and drug resistance insights.Frontiers in molecular biosciences · 2025Review
- Diagnostic Utility of MicroRNAs in Pancreatic Cancers.Cancers · 2024Review
- Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review.Journal of experimental & clinical cancer research : CR · 2024Review
- The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.International journal of molecular sciences · 2024Review
- Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation.Molecular cancer · 2023Review
- Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.International journal of molecular sciences · 2023Review
- Simultaneous Detection of Tumor Derived Exosomal Protein-MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis.ACS nano · 2023Article
- Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.International journal of molecular sciences · 2023Review
- Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.International journal of molecular sciences · 2023Review
- Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Current oncology (Toronto, Ont.) · 2022Review
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review.Cancer communications (London, England) · 2021Review
- Cellular microRNA detection with miRacles: microRNA- activated conditional looping of engineered switches.Science advances · 2019Article
- Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review.OncoTargets and therapy · 2019Article
- Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma.Cancers · 2018Article
- Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.BMC cancer · 2018Article
- A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma.Cancer management and research · 2018Article
- Article
- Microarray Analysis of the Expression Profile of Long Non-Coding RNAs Indicates lncRNA RP11-263F15.1 as a Biomarker for Diagnosis and Prognostic Prediction of Pancreatic Ductal Adenocarcinoma.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionLack of diagnostic makers results in loss of operation opportunity in that most patients are diagnosed at the late stage. Pancreatic cancer (PC) has been regarded as a fatal disease with a 5-year survival rate below 10%. Therefore, the development of diagnostic biomarkers for PC is in urgent need to control the mortality of the disease. MATERIALS AND
methodsThis is a case-control study including 640 plasma samples from healthy controls (HC), patients with benign pancreatic diseases (BPD), patients with PC; and patients with other gastrointestinal (GI) cancers. Eight biomarker candidates, including miR-20a, miR-21, miR-25, miR-155, miR-196a, miR-210, Macrophage Inhibitory Cytokine-1(MIC-1) and CA19-9, were evaluated to establish two diagnostic indexes in this study.
resultsThe plasma level of the six miRNAs and MIC-1, CA19-9 were elevated in PC patients compared with those of healthy controls (P<0.001). Among them, miR-20a, miR-21, miR-25, MIC-1 and CA19-9 could distinguish PC patients from those with other GI cancers or BPD. With multivariable logistic regression, we established two specific indexes for diagnosis of PC(Index1 contains miR-21, MIC-1 and CA19-9; Index2 contains miR-25, MIC-1 and CA19-9). In a randomized setting of 260 HC, 168 PC, 132 other GI cancers and 80 BPD patients, both indexes performed not only better sensitivity for PC but also better specificity to distinguish PC from other GI cancers than CA19-9 and individual biomarkers.
conclusionsThese results indicated that combination of biomarkers as a panel could improve diagnostic values compared with using a single marker. Such panels as illustrated in this study could provide novel plasmatic biomarker for PC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.